Axsome Therapeutics (AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with cataplexy ...

On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced the frequency of cataplexy ...

Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...

Nevertheless, the existing data do support such a theory: the disease is strongly associated with a T-cell receptor α gene variant, and 95% of patients with narcolepsy with cataplexy carry the ...

This is cataplexy. Strong emotions like excitement, surprise, and anger can set it off. At other times, you may experience sleep paralysis, which is like cataplexy. You temporarily can't speak or ...

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo ...

This novel drug is intended for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric narcolepsy patients aged six and older. The FDA’s decision fast-tracks the ...

AXS-12 (reboxetine), the norepinephrine reuptake inhibitor and cortical dopamine modulator achieved the primary endpoint in the ENCORE trial (NCT05059223), reducing the frequency of cataplexy ...